Ixekizumab

Ixekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetInterleukin 17A (IL-17A)
Clinical data
Pronunciationix-ee-KIZ-ue-mab[1]
Trade namesTaltz
AHFS/Drugs.comMonograph
MedlinePlusa616025
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60–81%[7]
MetabolismPresumably proteolysis
Elimination half-life13 days[8]
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6492H10012N1728O2028S46
Molar mass146192.34 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody.[9] The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.[10][11]

The most common side effects include upper respiratory infections, injection site reactions and fungal (tinea) infections.[12]

The drug was developed by Eli Lilly and Co. and is approved for the treatment of plaque psoriasis in the European Union and the United States as of 2016.[6][13]

Medical uses

In the United States, ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.[14] In the European Union it is indicated for the treatment of moderate-to-severe plaque psoriasis[6] and as a second-line therapy for active psoriatic arthritis.[6][10]

In studies, the drug reduced the Psoriasis Area and Severity Index by at least 75% (PASI75) in 82–89% of patients during the first three months of treatment (depending on the dosing scheme), and 40% of patients experienced a complete absence of psoriasis symptoms (PASI100). In the placebo group, PASI75 was reached in 4% of patients, and PASI100 in none; in the group of patients receiving etanercept, an older anti-psoriasis drug, PASI75 was reached in 48%. Until the 60th study week, 11–44% of ixekizumab treated patients relapsed (again, depending on the dosing scheme), as compared to 84% under placebo.[10][15]

Contraindications

The medication is contraindicated for patients with certain infections such as active tuberculosis.[10][contradictory]

Adverse effects

In studies, ixekizumab increased the rate of infections (27% of ixekizumab treated patients, compared to 23% under placebo), including severe ones (0.6% versus 0.4% under placebo). Other common side effects included injection site reactions such as redness and pain (13–17% versus 3%),[16] oropharyngeal pain (1%) and nausea (1–2%).[10] Other common adverse effects (≥5.0%) include nasopharyngitis, upper respiratory tract infection, arthralgia, headache, back pain, hypertension, bronchitis, diarrhea, sinusitis, and urinary tract infection.[17]

In a review of 18,025 patient years (n=6892 patients), no anaphylaxis was reported, no reactivation of tuberculosis, and low incidence rate of candida infection and serious infections was found. Incidence rates decreased or remained constant over time.[17]

Ixekizumab does not have an increased risk of adverse effects in the elderly.[18]

Overdose

Up to fourfold doses have been given in studies without causing serious side effects.[10]

Interactions

No interaction studies have been done. Ixekizumab and interleukin 17 are not known to interact with cytochrome P450 (CYP) liver enzymes. Since inflammation suppresses CYP activity, it is theorized that ixekizumab could neutralize this effect and lower blood plasma concentrations of drugs that are metabolized by CYP enzymes, such as warfarin.[10]

Pharmacology

Mechanism of action

Ixekizumab binds to interleukin 17 (IL-17A), a pro-inflammatory cytokine, and blocks its action. Among other things, IL-17A stimulates proliferation and activation of keratinocytes in the skin.[10] This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which binds to the interleukin-17 receptor.[19]

The antibody has affinity to the homodimer IL-17A and the heterodimer IL-17A/F, but not to other members of the interleukin 17 family.[10]

Pharmacokinetics

After subcutaneous injection, ixekizumab has a bioavailability of 60–81%;[7] bioavailability is higher in the thigh than the abdomen or arm.[7] Highest blood plasma concentrations are reached after four to seven days after a single dose.[8] With the usual dosing scheme (loading plus a dose every two weeks), steady state concentrations are reached in the eighth week on average.[10]

Like other antibodies, ixekizumab is probably degraded by proteolysis. Its elimination half-life is 14–18 days.[10][20] The volume of distribution is 7.11 L.[8] Mean clearance is 0.39 L/day.[8] There is no difference in rate of clearance between elderly and younger patients.[18] Increased body weight increases the volume of distribution and clearance rate.[8] Ixekizumab displays linear pharmacokinetics across doses.[20]

Pharmacokinetic data is similar for autoinjector pens and prefilled syringes.[7]

Chemistry

Ixekizumab is a complete monoclonal antibody of the subclass IgG4, consisting of two light chains and two heavy chains linked by disulfide bridges. Both heavy chains are glycosylated at the asparagine in position 296. In the hinge region, a serine is replaced by a proline to reduce formation of half-antibodies and heterodimers in the manufacturing process. The terminal lysine found in wild-type IgG4 is removed. The antibody is produced in Chinese hamster ovary cells.[9][21]

History

Clinical trials included a Phase II trial of patients with moderate to severe psoriasis,[19] and a Phase III open-label trial.[22][full citation needed]

Ixekizumab was approved by the US Food and Drug Administration (FDA) in March 2016, for the treatment of adults with moderate-to-severe plaque psoriasis[12] and by the European Medicines Agency (EMA) in April 2016.[6] The safety and efficacy of ixekizumab were established in three randomized, placebo-controlled clinical trials with a total of 3,866 participants with plaque psoriasis who were candidates for systemic or phototherapy therapy.[12] The FDA approved ixekizumab based on the evidence from three clinical trials of 1958 participants with moderate to severe psoriasis.[23] The trials were conducted in the US, Canada, Europe, Russia, Mexico, Chile, Argentina, Japan and Australia.[23]

In December 2017, the FDA approved it for active psoriatic arthritis.[24]

References

  1. ^ "12 Difficult-to-Pronounce Drug Names". Pharmacy Times. 7 February 2018. Archived from the original on 21 March 2018. Retrieved 22 March 2018.
  2. ^ "Ixekizumab (Taltz) Use During Pregnancy". Drugs.com. 27 November 2019. Retrieved 27 March 2020.
  3. ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  4. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
  5. ^ "Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 21 August 2019. Retrieved 27 March 2020.
  6. ^ a b c d e "Taltz EPAR". European Medicines Agency (EMA). 2 May 2016. Retrieved 27 March 2020.
  7. ^ a b c d Vu TT, Gooderham M, Papp K (November 2016). "Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis". Expert Review of Clinical Pharmacology. 9 (11): 1423–1433. doi:10.1080/17512433.2016.1242409. PMID 27690669.
  8. ^ a b c d e Kiwalkar S, Beier S, Deodhar A (October 2019). "Ixekizumab for treating ankylosing spondylitis". Immunotherapy. 11 (15): 1273–1282. doi:10.2217/imt-2019-0094. PMID 31530049.
  9. ^ a b "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
  10. ^ a b c d e f g h i j k Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
  11. ^ Cai Y, Fleming C, Yan J (July 2013). "Dermal γδ T cells--a new player in the pathogenesis of psoriasis". International Immunopharmacology. 16 (3): 388–391. doi:10.1016/j.intimp.2013.02.018. PMID 23499509.
  12. ^ a b c "FDA approves new psoriasis drug Taltz". U.S. Food and Drug Administration (FDA) (Press release). 22 March 2016. Retrieved 27 March 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  13. ^ "Taltz (ixekizumab) Injection". U.S. Food and Drug Administration (FDA). 3 May 2016. Retrieved 27 March 2020.
  14. ^ "Taltz- ixekizumab injection, solution". DailyMed. 23 August 2019. Retrieved 27 March 2020.
  15. ^ Klement A (4 June 2016). "Taltz". Österreichische Apothekerzeitung (in German) (14/2016): 12.
  16. ^ Shear NH, Paul C, Blauvelt A, Gooderham M, Leonardi C, Reich K, et al. (February 2018). "Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials". Journal of Drugs in Dermatology. 17 (2): 200–206. PMID 29462229.
  17. ^ a b Griffiths CE, Gooderham M, Colombel JF, Terui T, Accioly AP, Gallo G, et al. (June 2022). "Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure". Dermatology and Therapy. 12 (6): 1431–1446. doi:10.1007/s13555-022-00743-9. PMC 9209552. PMID 35624407.
  18. ^ a b Di Lernia V, Goldust M (August 2018). "An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly". Expert Opinion on Biological Therapy. 18 (8): 897–903. doi:10.1080/14712598.2018.1504016. PMID 30032682.
  19. ^ a b "Neue Antikörper in der Pipeline". Pharmazeutische Zeitung (in German) (12). 2012.
  20. ^ a b Dyring-Andersen B, Skov L, Zachariae C (April 2015). "Ixekizumab for treatment of psoriasis". Expert Review of Clinical Immunology. 11 (4): 435–442. doi:10.1586/1744666X.2015.1023295. PMID 25748485.
  21. ^ "Assessment report: Taltz" (PDF). European Medicines Agency. 25 February 2016. p. 7.
  22. ^ Clinical trial number NCT01624233 for "A Study in Japanese Participants With Moderate-to-Severe Psoriasis" at ClinicalTrials.gov
  23. ^ a b "Drug Trials Snapshots: Taltz". U.S. Food and Drug Administration (FDA). 22 March 2016. Retrieved 24 September 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  24. ^ "FDA approves Taltz for psoriatic arthritis in adults". Healio. 4 December 2017. Retrieved 23 September 2020.

Read other articles:

Jalur kereta api Binjai–Kuala

Jalur kereta api Binjai–KualaBekas Jembatan KA dekat dengan Stasiun KualaIkhtisarJenisLintas cabangSistemJalur kereta api rel ringanStatusTidak beroperasiTerminusBinjaiKualaOperasiDibangun olehDeli Spoorweg MaatschappijDibuka1890; 133 tahun lalu (1890) - 1902; 122 tahun lalu (1902)Ditutup2002; 22 tahun lalu (2002)PemilikPT Kereta Api Indonesia (pemilik aset jalur dan stasiun)OperatorWilayah Aset Divre I Sumatera Utara dan AcehKarakteristik lintasLintas datarData teknisLebar s...

 

 

Pertempuran Kanton (1857)

artikel ini perlu dirapikan agar memenuhi standar Wikipedia. Tidak ada alasan yang diberikan. Silakan kembangkan artikel ini semampu Anda. Merapikan artikel dapat dilakukan dengan wikifikasi atau membagi artikel ke paragraf-paragraf. Jika sudah dirapikan, silakan hapus templat ini. (Pelajari cara dan kapan saatnya untuk menghapus pesan templat ini) Pertempuran KantonBagian dari Perang Opium KeduaTentara Inggris perampokan toko komisariat di KantonTanggal28[1]－29 Desember 1857[2&...

 

 

Jerry Kemit

Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada November 2022. Topik artikel ini mungkin tidak memenuhi kriteria kelayakan umum. Harap penuhi kelayakan artikel dengan: menyertakan sumber-sumber tepercaya yang independen terhadap subjek dan sebaiknya hindari sumber-sumber trivial. Jika tidak dipenuhi, artikel ini ...

École normale supérieure de Lyon

École normale supérieure de LyonMotoL'enseignement par la recherche, pour la rechercheMoto dalam bahasa InggrisPendidikan lewat penelitian, untuk penelitianJenisGrande école (École normale supérieure)Didirikan1880Dana abadi€110 jutaPresidenJean-François Pinton[1]Staf administrasi350 peneliti, 220 profesorJumlah mahasiswa2.000Magister400LokasiLyon, PrancisKampusMonod (Sains) Descartes (Humanitas)Situs webwww.ens-lyon.eu École normale supérieure de Lyon (juga dikenal deng...

 

 

Zat biogenik

Sampel petroleum Zat biogenik adalah produk yang dibuat oleh atau dari bentuk kehidupan. Istilah ini mencakup konstituen, sekresi, dan metabolit tumbuhan atau hewan.[1] Dalam konteks biologi molekuler, zat biogenik disebut sebagai biomolekul. Sejarah Pada tahun 1930-an kimiawan Jerman Alfred E. Treibs pertama kali mendeteksi zat biogenik dalam minyak bumi sebagai bagian dari studinya tentang porfirin.[2] Berdasarkan penelitian ini, ada peningkatan pada tahun 1970-an dalam peny...

 

 

Pankaj Advani

Halaman ini berisi artikel tentang pemain biliar dan snooker India. Untuk sutradara, lihat Pankaj Advani (sutradara). Pankaj Advani di Paul Hunter Classic 2012 Pankaj Arjan Advani (lahir 24 Juli 1985) adalah seorang pemain biliar Inggris profesional dan mantan pemain snooker profesional asal India. Dalam mengakui prestasinya, Pemerintah India telah menganugerahkan beberapa penghargaan kepada Advani—Penghargaan Arjuna pada 2004, Rajiv Gandhi Khel Ratna pada 2006, dan Padma Shri pada 2009. ...

Philadelphia Union

Philadelphia UnionNama lengkapPhiladelphia UnionJulukanThe UBerdiri28 Februari 2008; 16 tahun lalu (2008-02-28)StadionSubaru ParkChester, Pennsylvania(Kapasitas: 18,500)PemilikKeystone Sports & Entertainment, LLCPresidenJay Sugarman Kevin DurantPelatih KepalaJim CurtinLigaMajor League Soccer2021Wilayah timur: ke-2Keseluruhan: ke-2Play-off: FinalSitus webSitus web resmi klub Kostum kandang Kostum tandang Musim ini Philadelphia Union adalah tim sepak bola profesional Amerika Serik...

 

 

Burnley Cricket Club

BurnleyTurf Moor cricket groundLeagueLancashire LeaguePersonnelCaptainDaniel PickupTeam informationFounded1833Home groundTurf MoorHistoryLancashire League wins18Worsley Cup wins10Ron Singleton Colne Trophy wins32nd XI League wins10Lancashire Telegraph Cup wins23nd XI League wins1Official websiteburnleycricketclub.com Burnley Cricket Club is a cricket club in the Lancashire League based at Turf Moor in Burnley, Lancashire. The club was a founder member of the Lan...

 

 

大字 (数字)

この項目には、一部のコンピュータや閲覧ソフトで表示できない文字が含まれています（詳細）。 数字の大字（だいじ）は、漢数字の一種。通常用いる単純な字形の漢数字（小字）の代わりに同じ音の別の漢字を用いるものである。 概要 壱万円日本銀行券（「壱」が大字） 弐千円日本銀行券（「弐」が大字） 漢数字には「一」「二」「三」と続く小字と、「壱」「�...

2020年夏季奧林匹克運動會波蘭代表團

2020年夏季奥林匹克运动会波兰代表團波兰国旗IOC編碼POLNOC波蘭奧林匹克委員會網站olimpijski.pl（英文）（波兰文）2020年夏季奥林匹克运动会（東京）2021年7月23日至8月8日（受2019冠状病毒病疫情影响推迟，但仍保留原定名称）運動員206參賽項目24个大项旗手开幕式：帕维尔·科热尼奥夫斯基（游泳）和马娅·沃什乔夫斯卡（自行车）[1]闭幕式：卡罗利娜·纳亚（皮划艇）&#...

 

 

Westhoek français

Westhoek françaisFlandre flamingante Pays France Région française Hauts-de-France Le Westhoek est la partie nord de la Flandre française. modifier  Le Westhoek français, appelé également Flandre flamingante[1], est un territoire situé en France qui correspond à la partie ouest du Westhoek et à la partie nord de la Flandre française. Sur le plan administratif, il correspond à peu près à l'arrondissement de Dunkerque dans le département du Nord. Sur le plan linguistique, il...

 

 

Corannulene

Corannulene Names IUPAC name Dibenzo[ghi,mno]fluoranthene[1] Other names [5]circulene Identifiers CAS Number 5821-51-2 Y 3D model (JSmol) Interactive imageInteractive image ChemSpider 10006487 Y PubChem CID 11831840 UNII KFD2X7NT86 Y CompTox Dashboard (EPA) DTXSID80474164 InChI InChI=1S/C20H10/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11(1)16-17(12)19(14)20(15)18(13)16/h1-10H YKey: VXRUJZQPKRBJKH-UHFFFAOYSA-N YInChI=1/C20H10/c1-2-12-5-6-14-9-10-15-8-7-13-4-3-11(...

Greater Poland

Historical region of west-central Poland Wielkopolska redirects here. For the voivodeship in Poland, see Greater Poland Voivodeship. For other uses, see Greater Poland (disambiguation). This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Greater Poland – news · newspapers · books · scholar · JSTOR (April 2014) (...

 

 

Illegal immigration to the United States

Immigration to the United States in violation of US law History of immigration enforcement actions, as reported by the Department of Homeland Security.[1] United States citizenship and immigration Immigration Immigration to the United States Emigration from the United States Immigration policy of the United States Effects of immigration to the United States Permanent Residency (Green Card) Refugees and asylum Diversity Immigrant Visa Illegal immigrants Deportation of Americans from th...

 

 

SMA Negeri 9 Padang

Koordinat: 0°55′39″S 100°25′40″E / 0.9276000°S 100.4279000°E / -0.9276000; 100.4279000 Artikel ini menggunakan kata-kata yang berlebihan dan hiperbolis tanpa memberikan informasi yang jelas. Silakan buang istilah-istilah yang hiperbolis tersebut. (Pelajari cara dan kapan saatnya untuk menghapus pesan templat ini) SMA Negeri 9 PadangInformasiDidirikan1988AkreditasiANomor Statistik Sekolah301086110009Nomor Pokok Sekolah Nasional10303506Kepala SekolahDra....

Athletics at the 1948 Summer Olympics – Men's 10 kilometres walk

Men's 10 kilometres walkat the Games of the XIV OlympiadJohn MikaelssonDates3 August (heats)7 August (final)Medalists John Mikaelsson Sweden Ingemar Johansson Sweden Fritz Schwab Switzerland← 19241952 → Athletics at the1948 Summer OlympicsTrack events100 mmenwomen200 mmenwomen400 mmen800 mmen1500 mmen5000 mmen10,000 mmen80 m hurdleswomen110 m hurdlesmen400 m hurdlesmen3000 msteeplechasemen4 × 100 m relaymenwomen4 × 400 m relaymenRoad eventsMarathonmen10 ...

 

 

Economy of Arkansas

Economy of ArkansasState quarterStatisticsGDP$176.24 billion[1]GDP per capita$54,347[2]Population below poverty line19.1%[3]Gini coefficient0.4773[4]Labor force1,349,512[5]Unemployment4.0%[6]Public financesRevenues$4,604 million[7]Expenses$4,604 million[7] The economy of Arkansas produced $176.24 billion of gross domestic product in 2023.[1] Six Fortune 500 companies are based in Arkansas, including the world's #1 corpor...

 

 

Min Zhou

American sociologist Min ZhouMin Zhou in 2006Academic backgroundEducationPhDAlma materState University of New York at AlbanyThesisThe Enclave Economy and Immigrant Incorporation in New York City's Chinatown (1989)Doctoral advisorJohn R. Logan[1]Other advisorsRichard Alba Min Zhou (Chinese: 周敏; born July 14, 1956 in Zhongshan) is a Chinese-born American sociologist. In 2023, she was elected to the National Academy of Sciences.[2] Zhou completed a bachelor's degree in E...

العلاقات الكوستاريكية المنغولية

العلاقات الكوستاريكية المنغولية كوستاريكا منغوليا   كوستاريكا   منغوليا تعديل مصدري - تعديل   العلاقات الكوستاريكية المنغولية هي العلاقات الثنائية التي تجمع بين كوستاريكا ومنغوليا.[1][2][3][4][5] مقارنة بين البلدين هذه مقارنة عامة ومرجعية لل�...

 

 

ألان تشارلزورث

هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (يونيو 2019) ألان تشارلزورث   معلومات شخصية الميلاد 17 سبتمبر 1903   الوفاة 21 سبتمبر 1978 (75 سنة)   غلن أيريس  [لغات أخرى]‏  مواطنة أستراليا  الحياة العملية ا�...